News | May 31, 2021
Sun Pharmaceutical’s internals remain strong: ICICI Securities
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Adjusted PAT declined 18.8% YoY
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
The company plans to enter the EU markets in FY22
The outlook for the US business remains good as respiratory pipeline (gAbraxane, gAdvair, gDulera) adds medium-term growth visibility.
The company is working closely with its six manufacturing partners in India
Subscribe To Our Newsletter & Stay Updated
